Continuous Glucose Monitoring in Inpatients

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to contribute to current research regarding the feasibility and accuracy of CGM in the hospital setting for both the medical and cardiovascular intensive care (ICU) patient populations.

Clinical Trial Description

The use of continuous glucose monitors (CGM) in the outpatient setting has dramatically increased as these devices continue to improve in both ease of use, accessibility, and accuracy. Federal Drug Administration (FDA) clearance of certain devices has now been granted in both pregnancy and automated insulin delivery systems. As the world has embraced the safety and efficacy of continuous glucose monitors in the outpatient setting, health systems have turned attention to the potential of utilizing these devices to improve glycemic control in the hospital setting. With the announcement of the FDA granting enforcement discretion regarding the use of CGM technology in the hospital setting during the COVID-19 pandemic, the result was an abundance of research evaluating the potential of CGM longevity in the hospital setting. The Standards of Care in Diabetes: 2023 reported that "preliminary data suggests that CGM can significantly improve glycemic management and other hospital outcomes." Additionally, a systematic review of 32 studies evaluated the accuracy of CGM in the intensive care unit, with a consensus of moderate to good accuracy. CGM in the hospital setting could provide a valuable tool in reducing hypoglycemia, hyperglycemia, and increasing time spent in normoglycemia. Other potential benefits of CGM include a broader view of glucose patterns, capture of asymptomatic hypoglycemia, reduced length of stay, and decreased cost. The Diabetes Technology Society organized the Hospital Consensus Guideline Panel in 2020, with the final report including the recommendation for additional research on the accuracy, data management, and patient-centered outcomes of CGM use in the inpatient setting. ;

Study Design

Related Conditions & MeSH terms

Hyperglycemia

Clinical Trial Details

NCT number	NCT06329297
Study type	Observational
Source	Parkview Health
Contact	Philip Roberts
Phone	260-266-2261
Email	Philip.roberts@parkview.com
Status	Not yet recruiting
Phase
Start date	April 2024
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01267448` - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia	Phase 4
Recruiting	`NCT03775733` - Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia	N/A
Completed	`NCT03482154` - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Active, not recruiting	`NCT05477368` - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes	N/A
Completed	`NCT03675360` - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial	N/A
Completed	`NCT00535600` - Effects of Bariatric Surgery on Insulin
Not yet recruiting	`NCT06159543` - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes	N/A
Recruiting	`NCT02885909` - Inpatient Blood Glucose Control in Taichung Veterans General Hospital	Phase 4
Recruiting	`NCT02885922` - The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
Completed	`NCT02012465` - Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients	Early Phase 1
Withdrawn	`NCT01488383` - Effect of Stevioside in Postpandrial Glucose in Healthy Adults	N/A
Completed	`NCT01805414` - Breakfast Nutrition and Inpatient Glycemia	N/A
Completed	`NCT01803568` - Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU	N/A
Completed	`NCT01810952` - The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients	Phase 4
Active, not recruiting	`NCT01247714` - Clinical Evaluation of a Specific Enteral Diet for Diabetics	N/A
Not yet recruiting	`NCT00846144` - The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients	N/A
Completed	`NCT00996099` - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients	N/A
Recruiting	`NCT00654797` - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2	Phase 2
Completed	`NCT00468494` - Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?	N/A
Completed	`NCT00394407` - Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes	Phase 4